Protocol Ledger

NCT07335601 · Phase II · RECRUITING

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Interventional Phase II clinical trial protocol NCT07335601 sponsored by Madrigal Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-29 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07335601
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07335601
Protocol FieldVerified Registry Value
NCT IdentifierNCT07335601
Consolidated Lead SponsorMadrigal Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2025-12-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI